Blog

The European healthcare technology and medical technology sectors have entered a period of definitive industrial maturity as of early 2026. This era is characterized by a fundamental shift away from the liquidity-fueled exuberance of the early 2020s toward a disciplined, metrics-driven environment where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. Within this landscape, the role of financial advisory has undergone a radical structural transformation. Traditional bulge bracket investment banks, while remaining dominant in the multi-billion-dollar "unicorn" exit and large-cap carve-out segments, are increasingly ceding the high-growth mid-market to a new class of specialist boutiques. These firms, often led by former entrepreneurs and clinicians, have emerged as the primary engines of liquidity for European innovation by bridging the gap between complex medical science and institutional financial engineering. &nbsp;&nbsp;The current cycle, spanning the 2024–2026 fiscal periods, is defined by a "Selective Recovery" and a profound "flight to quality". Following the post-pandemic valuation correction of 2023, the market has settled into a bifurcated state where premium assets, those with proprietary AI, robust clinical evidence, and full regulatory certification, command historically high multiples, while secondary assets face severe compression or are forced into distressed M&amp;A scenarios. This environment favors advisors who possess not only the balance sheet capabilities to execute complex cross-border transactions but also the domain expertise to conduct deep technical due diligence on the "software stack" and "clinical pathway" of a target.Nelson Advisors has emerged as a central reference point in the European healthtech and medtech advisory landscape going into 2026. Their unique positioning as "Strategic Architects" allows them to navigate a market that is transitioning from growth-at-all-costs to a disciplined industrial era. The firm’s influence is derived from its ability to identify the "four levers" that determine valuation in the current cycle: the AI premium, profitability/unit economics, vendor consolidation and regulatory/antitrust scrutiny. &nbsp;&nbsp;In 2025, Nelson Advisors played a pivotal role in articulating the shift toward "concentrated value." They noted that while deal volume might be lower than in previous years, deal value is increasing as acquirers focus on high-quality, "must-have" infrastructure. Their valuation matrix, frequently cited by industry analysts, provides a granular look at how different asset classes are priced in the February 2026 market.Read the report here <a href="https://www.healthcare.digital/single-post/european-healthtech-m-a-boutique-landscape">https://www.healthcare.digital/single-post/european-healthtech-m-a-boutique-landscape</a>

European HealthTech M&A Boutique Landscape

The global financial landscape in the first week of February 2026 was defined by a profound and systemic recalibration of risk, characterised by a transition from liquidity-driven expansion to a regime of rigid valuation discipline. This period, termed the "Warsh Shock" by market participants, saw a confluence of macroeconomic catalysts, ranging from shifts in Federal Reserve leadership to escalating geopolitical friction in the Middle East, trigger a significant drawdown in high-growth sectors.&nbsp; &nbsp; Within this broader market turbulence, the healthcare technology and digital health sectors experienced heightened volatility, acting as a microcosm of the tension between long-term innovation and short-term capital constraints.&nbsp; &nbsp;&nbsp; While the sell-off was broad-based, its impact on the healthcare spectrum was heterogeneous, revealing a stark divergence between established pharmaceutical conglomerates and nascent digital health platforms.Strategic Recommendations for the Post-Sell-Off Environment The volatility of February 2026 has served as a "cleansing event," stripping away speculative excess and highlighting the fundamental drivers of healthcare technology value. For professional investors navigating the "Warsh Shock" and looking toward the rest of 2026, several strategic imperatives emerge: &nbsp;&nbsp; 1. Prioritise Cash-Flow Resilience over Theoretical Growth: The market is rotating toward "safe assets" with recurring revenue. Investors should target established generics, outpatient service networks, and medtech firms with proven reimbursement codes (CPT/HCPCS). &nbsp;&nbsp; 2. Focus on "Labour Substitution" Technologies: With labor shortages and rising wage inflation in healthcare, technologies that offer "fundamental labour substitution", such as AI ambient scribes and automated MRI interpretation, will command a premium valuation. &nbsp;&nbsp; 3. Evaluate the "AI Infrastructure" Moat: Avoid companies that merely provide "AI-wrappers" for general-purpose LLMs. Instead, look for "AI-native" platforms that possess high-quality, clinical-grade proprietary data and are embedded into existing clinical workflows (e.g., Abridge, Commure). &nbsp;&nbsp; 4. Hedge through Defensive Healthcare Heavyweights: The performance of GSK and AstraZeneca during the sell-off underscores the value of maintaining exposure to pharmaceutical firms with robust pipelines and strong dividend histories. These firms provide stability while investors wait for the higher-beta digital health market to rebase. &nbsp;&nbsp; 5. Monitor Regulatory and Reimbursement Clarity: Securing inclusion in value-based care bundles or obtaining distinct CPT codes is now a primary diligence item. The regulatory environment in 2026 is "complex but thawing," and firms that connect their technical roadmaps to regulatory roadmaps will be the most successful in raising capital. &nbsp;&nbsp; Conclusion: The Darwinian Transition &nbsp;&nbsp; The healthcare technology sector on the stock exchange is currently navigating a "painful but necessary" transition. The sell-off of February 2026 was not a rejection of the sector's long-term potential, but a correction of its valuation architecture. As the "Warsh Shock" forces a return to fundamentals, the companies that survive will be those that have evolved from speculative experiments into essential components of the global healthcare infrastructure. &nbsp;&nbsp; The future holds a significant narrowing of the "trust gap" as companies demonstrate sustainable growth and software-like margins. For those who prioritise "real productivity over the temporary highs of central bank cash injections," the 2026 market sell-off may ultimately be viewed as the catalyst that ushered in the era of healthcare technology maturity.&nbsp; &nbsp;&nbsp; The integration of AI, the acceleration of M&amp;A and the stabilisation of digital health into "Health Tech 2.0" suggest that the sector's most resilient phase is yet to come.Read the full report here <a href="https://www.healthcare.digital/single-post/healthtech-stock-market-sell-off-analysis-february-2026">https://www.healthcare.digital/single-post/healthtech-stock-market-sell-off-analysis-february-2026﻿</a>

February 2026: HealthTech Stock Market Sell Off Analysis

European HealthTech this week is characterised by AI‑heavy care models preparing for the EU AI Act, continued investor focus on preventive and platform plays, and early‑stage funding/grant activity positioning startups for 2026–27 scale‑up.1. AI Act and regulatory pressure on HealthTech The EU AI Act is now in force, with high‑risk health AI systems facing core obligations from August 2026, including strict data governance, human oversight, documentation and transparency. Healthcare is explicitly treated as a high‑risk sector, meaning diagnostic and therapeutic AI, triage and decision‑support tools must move toward third‑party conformity assessment and AI sandboxes over the next 12–24 months. 2. Shift toward evidence and EHDS‑ready data 2026 is framed as a pivotal preparation year for the European Health Data Space, which will open up anonymised patient data for research, AI training and product validation under strict governance.​ HealthTech companies that build GDPR‑ and EHDS‑compliant data pipelines and use real‑world evidence to prove ROI are expected to out‑compete feature‑rich but evidence‑light rivals in reimbursement and hospital procurement.​ 3. Funding environment and thematic focus Analysis of Europe’s digital health capital flows emphasises that 2025 was driven by mega‑rounds in preventive health, TechBio and research solutions, and that 2026 will be judged far more on exits and durable business models than on headline round sizes.​ Preventive health is highlighted as the top‑funded area, with strong investor interest in AI‑enabled early detection, wellness/clinical hybrids and longitudinal health engagement platforms.​ 4. Notable company and product moves Ahead Health, a Zurich‑based AI‑native preventive health company, recently announced a 6 million USD round to expand its “personal health operating system” model across Europe via partnerships with clinics in Switzerland, Germany and planned expansion into Germany, the Netherlands and Austria.​ The company combines medically supervised testing with an AI platform that learns from individual patterns and research data, positioning itself directly in the high‑engagement preventive health and proprietary‑data segment investors are prioritising.​ 5. Integrated platforms over point solutions Sector commentary for 2026 stresses that standalone hardware and isolated point solutions are losing ground to integrated systems where software‑in‑a‑medical‑device strategies, interoperability and service layers determine adoption.​ HealthTech and MedTech vendors that can plug into EHRs, analytics and service workflows to deliver measurable reductions in hospital days and resource use are expected to gain procurement preference over narrow, single‑function apps.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;European MedTech this week is dominated by regulatory moves in Brussels, tightening timelines ahead of the 2026 MDR/IVDR and EUDAMED deadlines, alongside positioning by industry and investors for an “industrial maturity” phase rather than growth-at-all-costs.1. EU regulatory moves and MDR/IVDR direction The European Commission’s late‑2025 proposals to amend the MDR and IVDR are now shaping 2026 discussions, aiming to streamline processes, reduce administrative burden and improve predictability while maintaining safety.​ The package includes reforms to notified‑body oversight, clearer recertification clocks (e.g. 60‑day review, 15‑day issuance) and greater transparency, which, if adopted in 2026, could materially improve manufacturers’ planning for EU launches and renewals.​ 2. EUDAMED and transparency ramp‑up Four core EUDAMED modules (Actor registration, UDI/Devices, Notified Bodies &amp; Certificates, Market Surveillance) are now confirmed as fully functional, triggering a six‑month transition into mandatory use in 2026.​ From 28 May 2026, new MDR/IVDR devices must be registered in EUDAMED before EU market entry, with legacy devices and existing certificates following phased deadlines, pushing manufacturers to accelerate data and compliance readiness this year.​ 3. Harmonised standards and technical alignment A new Commission Implementing Decision in early 2026 updates harmonised standards under MDR, including neurosurgical implants, biological and clinical evaluation, sterilisation, non‑active surgical implants, breathing‑gas pathways and small‑bore connectors.​ MedTech manufacturers are being advised to review gap analyses and update technical documentation and conformity strategies now to avoid last‑minute certification risk as enforcement tightens into 2026.​ 4. Strategic outlook: “industrial maturity” and AI regulation Strategic commentary on 2026 positions European MedTech and HealthTech at an inflection point, moving from fragmented, speculative growth to a disciplined era focused on profitable efficiency, robust unit economics and regulatory resilience.​ The upcoming enforcement of the EU AI Act for high‑risk medical AI systems in August 2026 is already acting as a binary filter for investment, with high‑risk tools needing strong data governance, human oversight and transparency to remain viable deal targets.​ 5. Capital and deal environment signals Analysis of Europe’s digital health and MedTech funding coming into 2026 highlights that 2025 was marked by several mega‑rounds (e.g. Ōura, Isomorphic Labs, Neko Health, Amboss), and that 2026 will be judged more on exits than headline rounds.​ The UK and Nordics, particularly Finland, are flagged as current powerhouses for digital health capital, with preventive health, TechBio and AI‑driven research solutions remaining priority themes for European and US investors active in MedTech‑adjacent plays.​To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 6th February 2026

Nelson Advisors featured in First World HealthTech’s article ‘Technical requirements and specifications for Health Records’. &nbsp; · &nbsp; &nbsp; &nbsp; Apple has updated its Health Records and Share with Provider features to support HL7 FHIR R4, a widely used healthcare data-exchange standard that helps apps and hospitals share structured information with electronic health record (EHR) systems.· &nbsp; &nbsp; &nbsp; The tech giant did not make an official announcement about the new capabilities, but social media platforms, specifically LinkedIn, were abuzz about the upgrade, which allows certain Apple Health-aggregated data to flow more seamlessly into hospital EHR systems. · &nbsp; &nbsp; &nbsp; Healthtech consultancy Nelson Advisors highlighted in an article the advantages of having features that support FHIR R4: “The structured, resource-based design of FHIR R4 provides the ideal foundation for artificial intelligence applications. By moving data into standardised FHIR formats, organisations can increase interoperability from as low as 11% to 66%.” · &nbsp; &nbsp; &nbsp; Other comments about Apple’s quiet upgrade included the need to ensure clinicians do not get flooded by data, and for any data exchange to be done responsibly and effectively.&nbsp; Source: <a href="https://firstwordhealthtech.com/story/7093917">https://firstwordhealthtech.com/story/7093917</a>About First World HealthTech &nbsp; FirstWord is an innovative industry intelligence leader serving over 260,000 HealthTech and pharma professionals worldwide. FirstWord's products and services are designed to help you gain a competitive edge by making key decisions with speed and confidence. FirstWord HealthTech PLUS and Pharma PLUS deliver up-to-the-minute personalised and comprehensive news, insight, analysis, and physician views of importance to your products and company. FirstWord Dossier reports provide expert views from industry on important trends and challenging issues. Covering over 40 disease areas, FirstView and Therapy Trends reports offer unique insights into current and future market dynamics and treatment landscapes through quantitative surveys with physicians and in-depth interviews with the world's leading KOLs. &nbsp; <a href="https://firstwordhealthtech.com/" data-mce-href="https://firstwordhealthtech.com/">https://firstwordhealthtech.com/</a>

Nelson Advisors featured in First World HealthTech’s article ‘Technical requirements and specifications for Health Records’

Strategic owners and PE appear to be exiting classic EHR assets because the legacy EHR business model is becoming low‑return, capital‑intensive and politically exposed, even as the data itself becomes more valuable for AI. The value is migrating to cloud, data platforms and AI infrastructure rather than to regulated transactional EHR software licenses.What’s happening in a few specific cases - EMIS, CernerUnitedHealth / Optum UK (EMIS)UnitedHealth acquired EMIS in 2023 for about £1.24bn to deepen its UK health tech presence.It is now running a sale process for Optum UK, whose core asset is EMIS; reports suggest sponsor bids around £1bn+, with PE firms like TPG and Blackstone circling. This looks like a portfolio reshaping and capital recycling move: Optum can keep benefiting from UK data/relationships through partnerships while freeing capital for higher‑growth analytics, virtual care and AI plays elsewhere. Oracle / CernerOracle bought Cerner for over $28bn in 2022 as a healthcare data beachhead.​ Cerner’s rollout in large projects such as the U.S. VA has been troubled, with cost overruns and customer dissatisfaction, and Oracle Health’s share has “declined substantially” versus Epic. TD Cowen now reports Oracle is evaluating selling Cerner and cutting 20–30k jobs to help finance a massive, roughly $156bn AI datacentre build related to a huge OpenAI contract.​ In other words, Oracle appears to view cloud + AI infra as a far better use of balance sheetthan grinding away in an EHR segment where it is losing share and returns. Why exit EHR when AI needs the data? EHR economics are maturing and squeezed Global EHR revenues are still growing (mid‑single to high‑single‑digit CAGR to 2030), but this is now a mid‑growth, infrastructure‑like market rather than a hyper‑growth SaaS story. Penetration in OECD health systems is high; growth is mainly upgrades, add‑on modules and emerging markets, with intense pricing pressure from public purchasers. Vendors face rising costs to meet regulatory, interoperability, cybersecurity and AI‑integration requirements, which erodes margins and makes large‑scale, on‑premise or hosted EHRs less attractive relative to lighter‑weight data/AI products. The value is shifting from “system of record” to “data and AI layer” EHRs originated as transactional systems and digital filing cabinets; the strategic value now lies in platforms that can aggregate data from multiple sources, normalise it and power AI models and real‑time decision support. Health systems increasingly want modern data platforms and analytics layers that sit on top of EHRs, rather than being locked into a single monolithic vendor stack. This enables owners to divest the heavy, regulated EHR asset but still participate in AI value creation via cloud, interoperability hubs, data warehouses and model‑as‑a‑service offerings that ingest EHR data under contract. Strategic capital is being reallocated to AI infrastructure and cloud Oracle faces a massive capex requirement for GPU‑rich datacentres to support a multiyear OpenAI cloud contract, with estimates of $156bn in required capital spend; selling Cerner is one option explicitly floated to fund this.​ The risk‑adjusted return on hyperscale cloud + AI infrastructure, if Oracle wins enough workload, likely beats the return on trying to fix Cerner, regain share from Epic, and fund long, politically sensitive deployments. UnitedHealth, similarly, can deploy capital into faster‑growing data analytics, care delivery and insurance adjacencies globally rather than continuing to own a UK GP EHR business that behaves more like regulated utility infrastructure. Regulatory, political and reputational risk is high UK primary‑care EHR (EMIS, System C etc.) is deeply entangled with the NHS, patient data sovereignty concerns and scrutiny of foreign ownership; this creates political risk, especially for a US insurer like UnitedHealth. In the U.S., Cerner’s contract at the Department of Veterans Affairs has been plagued by technical problems and negative press, damaging Oracle’s reputation and increasing its exposure to government programme risk.​ For diversified strategics, exiting or partially exiting EHR can de‑risk the portfolio, while they keep non‑ownership access to data through long‑term hosting, analytics or services contracts. For PE, EHR now looks like a classic yield / platform trade, not a long‑duration growth story Core EHR vendors have recurring revenue, high switching costs and entrenched positions, which suits PE’s appetite for cash‑generative, defensible assets. CVC’s playbook at System C (platform consolidation, oncology bolt‑on, cross‑selling across health and social care) sets up a secondary buyout or strategic sale once operational levers are pulled. Once value‑creation milestones are achieved and leverage is optimised, recycling into the next wave of health data/AI or specialised workflow software can offer better risk‑adjusted upside than holding EHRs through their slow‑growth, high‑capex AI retrofitting phase. How AI interacts with EHRs (and who captures value) Leading EHR vendors are actively embedding gen‑AI into documentation, search and decision support, with dozens to over a hundred live or in‑development use cases (note writing, chart summaries, ambient scribing, agentic assistants etc.). AI performance improves as it accesses broader, more longitudinal and multi‑source data (labs, imaging, devices, claims, SDOH), which often requires data platforms that span multiple EHRs rather than any single vendor’s silo. Cloud vendors and horizontal AI platforms (including those building health‑specific data fabrics) are therefore well positioned to capture outsized value, while EHRs increasingly behave as regulated transaction systems feeding those layers. How to interpret this as an investor / strategist EHR data are indeed critical for healthcare AI, but owning the EHR vendor is no longer the only or best way to monetise that data; data‑sharing, interoperability and analytics contracts can give you the data flows without owning the legacy software stack. Strategics like Oracle and UnitedHealth are pruning capital‑intensive, politically fraught EHR assets to double down on cloud, AI and services where they see higher growth and returns, while PE steps in to own and optimise the “infrastructure” layer. The next leg of value likely sits in:Vendor‑agnostic health data platforms and interoperability hubs. AI‑native clinical workflow tools that sit on top of EHRs. Niche, high‑acuity modules (oncology, ICU, peri‑op) with clear ROIContact us to discuss how Nelson Advisors can help your Healthcare AI or HealthTech business. <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Why are strategic owners and private equity exiting the Electronic Health Records market?

ARR is now the standard way to describe recurring SaaS and API revenue in health and life sciences, including the AI portion (“AI ARR”) that can include both fixed subscriptions and committed usage. Health systems and payers like predictable recurring spend versus capex, so a subscription spine (monthly or annual terms, multi‑year where you can get it) usually helps procurement and valuation, and supports CAC/LTV math. From an investor/M&amp;A lens, ARR (and increasingly AI‑ARR) is the language for benchmarking efficiency and multiples, even when underlying contracts combine fixed and variable elements. The catch is that most healthcare AI cost and value drivers scale with volume, complexity and outcomes, not just “number of logos,” which is where alternatives come in.Key limitations of pure flat ARR Workload heterogeneity: a flat per‑site or per‑org fee misprices a 50‑bed community hospital versus a large tertiary center processing millions of notes or studies; either your margins get crushed or your smaller sites balk. Cloud/LLM cost volatility: generative AI costs can range from low six figures to several million per year per health system depending on note volume and token usage, so a flat subscription can be either underwater or uncompetitive. Reimbursement and budgets: some AI, especially diagnostics, is funded per exam/procedure (CPT‑linked), which makes pure SaaS ARR awkward unless you translate it back into per‑exam economics that fit reimbursement. Perceived risk: providers faced with uncertain ROI, integration risks and governance overhead may resist large fixed commitments, preferring “pay as you go” or outcome‑linked deals that feel less one‑way. So ARR works best as the accounting wrapper and investor metric, not as “one flat annual price for everything” in the commercial model.Main alternative / complementary models 1. Usage‑based (per unit of work)Pricing tied directly to a unit such as exam, encounter, note, claim, message, or member‑month.Common forms in healthcare AI:Per exam or study (imaging, retinal screening, cardiac CT). Per clinical encounter or note (scribes, CDS, summarisation). Per transaction or claim (RCM, prior auth, denials management). Pros: Aligns spend with actual usage and often with reimbursement; easy entry for smaller sites; can scale well in high‑volume settings. Cons: Revenue volatility, harder forecasting; incentives to under‑use; can hit budget ceilings when volume spikes. In practice, most “usage‑based” AI contracts in healthcare are still rolled up into ARR as long as there is a committed run‑rate or floor.2. Hybrid: base platform ARR + usage This is emerging as the dominant pattern for AI agents and infra: a minimum recurring platform fee plus metered components.Structure:Base subscription for access, integrations, support, and a committed volume band. Overage or higher tiers for extra volume, premium features (real‑time, coding, summarisation), or extra “bots/modules.” Pros: Preserves ARR and predictability while capturing upside from heavy users; covers fixed infra and go‑live costs; easier to sell than pure usage. Cons: More complex to explain; requires solid metering and billing systems; procurement may negotiate hard on overage rates. Many vendors explicitly report “AI ARR” that combines the committed subscription and recurring usage overages for AI features.​3. Seat‑, role‑ or site‑based SaaSClassic SaaS patterns still show up, especially for front‑office and workflow AI.Variants:Per user/seat (clinician, coder, scheduler). Per location (clinic, department, practice). Per enterprise tier (small/medium/large health system tiers).​ Pros: Familiar to buyers; simple to model; can be combined with non‑AI modules. Cons: Often misaligned with LLM cost drivers; also weakly correlated with incremental value once AI is doing work autonomously in the background. This works better when the AI is assisting a clearly identified user (e.g., scribe for individual clinicians) than when it is a back‑end engine.4. Outcome‑ / performance‑based and risk‑sharing Revenue linked to measurable outcomes (e.g., fewer readmissions, reduced ER visits, higher quality scores, higher reimbursement yield).Examples and context:Value‑based pharma and digital therapeutic contracts where payment is tied to real‑world performance, now being scaled using AI‑enabled RWE infrastructure. AI decision support or population health tools that improve metrics in value‑based contracts, where the vendor takes a share of savings or upside. Pros: Strong alignment with health system and payer incentives; potentially large upside; differentiated story with payers and regulators. Cons: Heavy measurement and data burden; long feedback loops; tricky contract design and attribution; not yet scalable across many indications. This tends to work as a layer (success fees, bonuses, shared savings) on top of a base platform fee rather than a pure performance‑only structure.5. Device‑, maintenance or bundle‑embedded AI economics embedded in a hardware, service, or managed‑service bundle.Patterns:Medtech: AI features bundled into device pricing, service contracts, or “per procedure” disposables. Managed service: vendor runs a function (coding, safety netting, prior auth) and bakes AI into a per‑unit fee. Pros: Fits existing purchasing and reimbursement rails; hides AI complexity; can accelerate adoption in conservative environments. Cons: AI value can get “lost” inside the bundle; harder to isolate AI ARR and justify AI‑specific multiples; medtech‑style capital budgets might cap growth. Picking the model: practical guide For a given healthcare AI product, you can usually answer three questions to pick the spine and the overlays:What is the natural unit of value?Exams, encounters, notes, claims, member‑months, or outcome metrics (e.g., fewer ER visits) suggest usage‑ or outcome‑linked components. How is it actually funded today?If reimbursement is per procedure or bundled payment, mirror it with per‑unit or per‑bundle pricing; if it sits in IT/operations budgets, a tiered SaaS with usage overage is often cleaner. What story do you want for investors and buyers?Use ARR and AI‑ARR as the primary reporting metrics, even if contracts are hybrid, so you can show durable recurring revenue, expansion, and operating leverage. In short, ARR should be the reporting layer and contract chassis, but the optimal healthcare AI business model is usually ARR‑anchored, usage‑sensitive, and progressively more outcome‑linked as your evidence matures.Contact us to discuss how Nelson Advisors can help your Healthcare AI or HealthTech business. <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

European HealthTech M&A Boutique Landscape

February 2026: HealthTech Stock Market Sell Off Analysis

This Week in European MedTech and HealthTech: 6th Februar...

Nelson Advisors featured in First World HealthTech’s arti...

Why are strategic owners and private equity exiting the E...

Is ARR the right business model for Healthcare AI? What a...